

LUTRONIC WEEKLY REPORT

20180716~20180720

Industry News

✓ OD-OS sought the patent revocation in order to manufacture and market the Navilas laser system with microsecond pulsing technology. The Navilas has computer-assisted laser delivery and digital documentation, the release said. → [Iridex MicroPulse patent revoked in Europe](#)(Healio/July 17)


✓ Swedish firm Xbrane Biopharma and Germany's Stada Arzneimittel have linked up to co-develop Xlucane, a biosimilar version of top-selling ophthalmic drug Lucentis (ranibizumab), which is marketed by Swiss pharma giants of Novartis and Roche's. To enter into this agreement, Stada will make an upfront payment to Xbrane of 7.5 million euros (\$8.8 million). → [Xbrane and Stada Arz look to co-develop Lucentis biosimilar](#) (ThePharmaletter/ July 13)

Korean Stock Market News

✓ US-Japan global commodities have recovered up to 16% in 3 months → [Domestic bio stocks have languished, while global healthcare funds are 'bullish'](#) (Maeil Economic Daily / July 19)

✓ After six or eight injections, abicipar, a DARPIn molecule, demonstrated similar efficacy as 13 injections of Lucentis (ranibizumab, Genentech) in both the CEDAR and SEQUOIA trials after the first year. → [Fewer doses of abicipar yield similar efficacy as ranibizumab for wet AMD](#) (Healio/July 19)

STOCK PERFORMANCE



9.19% of shares (common stock) held by Foreign Investors as of July 20

* IR Book Download Link (July 2018 Ver.)

Website: www.international.lutronic.com

Contact : Ji Hye Choi, Communication team – jh.choi@lutronic.com/ +82-70-4714-6024